The global cancer supportive care medicine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cancer supportive care medicines are the kinds of drugs that are used to alleviate the harmful side effects caused by cancer treatment through protecting certain cells or organs. Among these treatment methods, chemotherapy is broadly known to cause side effects such as loss of appetite, severe nausea and vomiting, among others. Thus, the rising prevalence of cancer is acting as the pivotal factors responsible for the increased demand for these medicines. Adding to this, the global cancer supportive care medicine market is also driven by extensive R&D along with the new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is an antiemetic drug that is indicated for the control of severe nausea and vomiting.

Some key players operating in the market include Amgen Inc., Novartis International AG, and Merck & Co., Inc., among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Class

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  Amgen Inc., Novartis International AG, and Merck & Co., Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Cancer Supportive Care Medicine Market Report by Segment

By Drug Class

    • G-CSFs (Granulocyte Colony-Stimulating Factor)

    • ESAs (Erythropoiesis Stimulating Agent)

    • Antiemetics

    • Bisphosphonates

    • Opioids

    • NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

    • Topical

    • Others

Global Cancer Supportive Care Medicine Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa